Biotricity, Inc.

Report azionario OTCPK:BTCY

Capitalizzazione di mercato: US$2.3m

Biotricity Gestione

Criteri Gestione verificati 4/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Waqaas Al-Siddiq

Amministratore delegato

US$732.0k

Compenso totale

Percentuale dello stipendio del CEO65.57%
Mandato del CEO12.1yrs
Proprietà del CEOn/a
Durata media del management5.5yrs
Durata media del Consiglio di amministrazione9yrs

Aggiornamenti recenti sulla gestione

Recent updates

Articolo di analisi • Jan 26

Investors Give Biotricity, Inc. (NASDAQ:BTCY) Shares A 38% Hiding

Biotricity, Inc. ( NASDAQ:BTCY ) shareholders that were waiting for something to happen have been dealt a blow with a...
Articolo di analisi • Oct 26

Many Still Looking Away From Biotricity, Inc. (NASDAQ:BTCY)

When close to half the companies operating in the Healthcare Services industry in the United States have price-to-sales...
Seeking Alpha • Aug 15

Biotricity GAAP EPS of -$0.09, revenue of $2.06M

Biotricity press release (NASDAQ:BTCY): Q1 GAAP EPS of -$0.09. Revenue of $2.06M (+17.0% Y/Y).
Seeking Alpha • Jul 28

Biotricity, Inc.: A First Take

Today, we take our first look at a small medical device maker called Biotricity. Impressive growth projections lie ahead for this Busted IPO as it recently launched several important new products. An investment analysis follows in the paragraphs below. Facts do not cease to exist because they are ignored."― Aldous Huxley Today, we put Biotricity, Inc. (BTCY) in the spotlight for the first time. This medical device company finds itself in "Busted IPO" territory. However, a few new product launches should help the company deliver impressive revenue growth in the quarters and years ahead. An analysis follows below. Seeking Alpha Company Overview: This small medical device/technology solution concern is based just outside of San Francisco. The company provides biometric data monitoring solutions. Biotricity is focused on the delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. The stock trades for around $1.25 a share and sports an approximate market capitalization of $70 million. The company describes itself as: Biotricity is a modern medical technology company focused on delivering innovative, remote biometric monitoring solutions to the medical and consumer markets, including diagnostic and post-diagnostic solutions for chronic conditions and ​lifestyle improvement" The company's product portfolio of hardware devices and software solutions are all designed in house. Fourth Quarter Results: On July 14th, the company reported fourth quarter results. Revenues rose 80% on a year-over-year basis to $2.15 million as Biotricity posted a non-GAAP net loss of 11 cents a share. Both top and bottom line numbers were in-line with the consensus. For the full 2022 fiscal year, Biotricity had $7.7 million worth of sales, an 126% increase from FY2021. The company had a full year non-GAAP loss of 66 cents a share, 48 cents a share if you drop one-time items. The company noted on its earnings press release some notable product news during the quarter: The launch of its wireless wearable holter patch device, Biotres. This is a development leadership says represents the future of Remote Patient Monitoring. Unveiled Biokit, a personal medical device kit for integration into the Biotricity ecosystem. Launched Bioheart, a first-of-its kind continuous heart rhythm recorder and personal heart lifestyle solution. Released Biocare Cardiac, a personal, cardiac health application for individuals diagnosed with, or at risk for, cardiovascular disease. Leadership seems particularly excited by two of these launches. Bioheart, its cardiac monitor now directly available to consumers offers the same continuous heart monitoring technology used by physicians. The patient can now manage heart conditions with retrospective snapshots and long-term data collection in a state-of-the-art manner. The device is worn directly around the chest and goes for just under $200 on Amazon. Bioheart measures your heart's electrical activity with high accuracy. The device is small and lightweight, and at approximately 2.5 inches in diameter can fit in the palm of your hand. It can be set up in a few minutes, starting by downloading the Bioheart app. This device can improve remote patient monitoring significantly and is very relevant to senior citizens as doctors can use this data to diagnose and treat heart rhythm irregularities with minimal in-person visits. In this way it advances Telehealth. The company believes this adds an approximate $1.25 billion annual market to its target population.
Articolo di analisi • Apr 09

Is Biotricity (NASDAQ:BTCY) Using Debt In A Risky Way?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Articolo di analisi • Dec 11

Does Biotricity (NASDAQ:BTCY) Have A Healthy Balance Sheet?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Seeking Alpha • Aug 31

Biotricity: Capital Raise Leads To Buying Opportunity

BTCY recently announced a capital raise, leading to a sudden and significant decrease in the share price. With likely catalysts ahead, and continued stellar growth in its core business, the recent share price drop presents a compelling buying opportunity. In conjunction with the secondary offering, BTCY has now been uplisted to Nasdaq, providing more visibility and liquidity in the stock. Anapp currently under development by BTCY could blow the top off all current management guidance and analyst estimates. While there are certainly risks, the stock could conceivably double over the next year.

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Waqaas Al-Siddiq rispetto agli utili di Biotricity?
DataCompenso totaleStipendioUtili della società
Mar 31 2026US$732kUS$480k

-US$3m

Dec 31 2025n/an/a

-US$5m

Sep 30 2025n/an/a

-US$5m

Jun 30 2025n/an/a

-US$6m

Mar 31 2025US$1mUS$480k

-US$12m

Dec 31 2024n/an/a

-US$14m

Sep 30 2024n/an/a

-US$16m

Jun 30 2024n/an/a

-US$18m

Mar 31 2024US$1mUS$480k

-US$15m

Dec 31 2023n/an/a

-US$15m

Sep 30 2023n/an/a

-US$17m

Jun 30 2023n/an/a

-US$18m

Mar 31 2023US$1mUS$480k

-US$20m

Dec 31 2022n/an/a

-US$21m

Sep 30 2022n/an/a

-US$23m

Jun 30 2022n/an/a

-US$29m

Mar 31 2022US$887kUS$480k

-US$30m

Dec 31 2021n/an/a

-US$30m

Sep 30 2021n/an/a

-US$27m

Jun 30 2021n/an/a

-US$19m

Mar 31 2021US$891kUS$390k

-US$16m

Dec 31 2020n/an/a

-US$16m

Sep 30 2020n/an/a

-US$14m

Jun 30 2020n/an/a

-US$13m

Mar 31 2020US$2mUS$390k

-US$11m

Compensazione vs Mercato: La retribuzione totale di Waqaas ($USD 732.00K ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 653.62K ).

Compensazione vs guadagni: La retribuzione di Waqaas è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Waqaas Al-Siddiq (41 yo)

12.1yrs
Mandato
US$732,000
Compensazione

Dr. Waqaas Al-Siddiq, PhD, has founded Biotricity Inc. (formerly known as iMedical Innovations Inc.) in July 2014 and has been its Chairman, President and Chief Executive Officer since July 2014. Dr. Al-Si...

Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Waqaas Al-Siddiq
Founder12.1yrsUS$732.00kNessun dato
S. Ayanoglou
Chief Financial Officer8.8yrsUS$562.00k0%
$ 0
Amjad Talpur
Senior Director of Operationsno dataNessun datoNessun dato
Matt Zabel
Vice President of Sales & Strategyno dataNessun datoNessun dato
Amir Ali
Chief Development Officerno dataNessun datoNessun dato
Spencer LaDow
CISO and Executive VP of Engineering & Regulatoryless than a yearNessun datoNessun dato
Fareeha Siddiqui
Executive Vice President of Healthcare Solutions2.2yrsNessun datoNessun dato
5.5yrs
Durata media

Gestione esperta: Il team dirigenziale di BTCY è esperto e expertise (durata media dell'incarico 5.5 anni).

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Waqaas Al-Siddiq
Founder12.1yrsUS$732.00kNessun dato
John Simpson
Chair of Scientific & Medical Alliance Board and Chair of Science Alliance Board6.4yrsNessun datoNessun dato
Daniel Sands
Member of the Board of Advisors10.3yrsNessun datoNessun dato
Ronald McClurg
Independent Director4.3yrsUS$16.00k0%
$ 0
David Rosa
Independent Director10.3yrsUS$60.00k1.16%
$ 26.8k
J. Rice
Member of the Board of Advisors10.2yrsNessun datoNessun dato
John Rother
Member of the Board of Advisors10.3yrsNessun datoNessun dato
Thomas Nelson
Member of the Board of Advisors10.2yrsNessun datoNessun dato
Donald Cross
Member of Scientific & Medical Alliance Board7.8yrsNessun datoNessun dato
Edward Lazaga
Member of Scientific & Medical Alliance Board7.8yrsNessun datoNessun dato
Imran Mohiuddin
Member of Scientific & Medical Alliance Board7.8yrsNessun datoNessun dato
Radoslaw Kiesz
Member of Scientific & Medical Alliance Board7.8yrsNessun datoNessun dato
9.0yrs
Durata media
68yo
Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di BTCY sono considerati esperti (durata media dell'incarico 9 anni).

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/08/18 03:18
Prezzo dell'azione a fine giornata2026/08/18 00:00
Utili2026/03/31
Utili annuali2026/03/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Biotricity, Inc. è coperta da 2 analisti. 0 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Kevin DedeH.C. Wainwright & Co.
Jason WittesNorthland Capital Markets